Insulin sensitizers in treatment of nonalcoholic fatty liver disease： Systematic review
AIM： To summarize the evidence available for the clinical effectiveness of insulin sensitizers in the treatment of nonalcoholic fatty liver disease （NAFLD） systematically. METHODS： Relevant articles were located using computer-assisted searches of Medline （1966-March 2006）, EMBASE （1988-March 2006）,...
Gespeichert in:
| Veröffentlicht in: | World journal of gastroenterology : WJG 2006-12, Vol.12 (48), p.7826-7831 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7831 |
|---|---|
| container_issue | 48 |
| container_start_page | 7826 |
| container_title | World journal of gastroenterology : WJG |
| container_volume | 12 |
| creator | Chavez-Tapia, Norberto-C Barrientos-Gutierrez, Tonatiuh Tellez-Avila, Felix-I Sanchez-Avila, Francisco Montano-Reyes, Maria-Antonieta Uribe, Misael |
| description | AIM： To summarize the evidence available for the clinical effectiveness of insulin sensitizers in the treatment of nonalcoholic fatty liver disease （NAFLD） systematically.
METHODS： Relevant articles were located using computer-assisted searches of Medline （1966-March 2006）, EMBASE （1988-March 2006）, CINAHL （1982-March 2003）, Educational Resource Information Center （1966-March 2006）, Library, Information Science ＆ Technology Abstracts （1967-March 2006）, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects （1994-2006）, dissertations in ProQuest and FirstSearch databases. Manual searches were made in the abstracts from meetings of the American Gastroenterological Association （1999-2006）, and the American Association for the Study of Liver Diseases （2003-2005）. Studies were retrieved using the following selection criteria： （1） clinical trials using insulin sensitizers in subjects with NAFLD, （2） adult patients, （3） published as full manuscripts or abstracts, and （4） English, Spanish, German, and French languages only. Data were abstracted independently by two reviewers following standardized procedures. A face-toface comparison of data was conducted to ensure the completeness and reliability of the abstraction process.
RESULTS： Nine studies were included, six using metformin and three using thiazolidinediones. Only two studies were placebo-controlled trials. The median sample size for all studies was 18 subjects. In the placebo-controlled trials, metformin improved insulin resistance markers and liver function tests, but not histological scores. In the single-arm trials, metformin and thiazolidinediones improved insulin resistance markers and liver function tests, and beneficial histological changes were reported. There is limited high-quality information available from which to draw categorical conclusions about the clinical use of insulin sensitizers in NAFLD.
CONCLUSION： Current information indicates that the use of insulin sensitizers in NAFLD improves insulin resistance and liver function. Histological changes must be corroborated in randomized controlled trials. |
| doi_str_mv | 10.3748/wjg.v12.i48.7826 |
| format | Article |
| fullrecord | <record><control><sourceid>wanfang_jour_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4087550</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>23624794</cqvip_id><wanfj_id>wjg200648017</wanfj_id><sourcerecordid>wjg200648017</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-f367e18aa5a8f1af099b3c5f05889f77097e5631a465f54539c059a3537b7d673</originalsourceid><addsrcrecordid>eNpVkc1uEzEUhS1ERUNhzwqNEGI3qf_t2SChip9KlVgUFqysm4mdOMzYre1JFB6FZ-GdeAUcJSqwsi2f-91z70HoBcFzpri-3G1W8y2hc8_1XGkqH6EZpaRrqeb4MZoRjFXbMarO0dOcNxhTxgR9gs6Jorje9Ax9uw55Gnxosg3ZF__DptzUZ0kWymhDaaJrQgww9HEdB983DkrZN4Pf2tQsfbaQ7e9fP5vbfS52hFIVyW693T1DZw6GbJ-fzgv09cP7L1ef2pvPH6-v3t20PRe4tI5JZYkGEKAdAYe7bsF64bDQunNK4U5ZIRkBLoUTXLCux6IDJphaqKVU7AK9PXLvpsVol331nGAwd8mPkPYmgjf__wS_Nqu4NRxrJQSugNdHwA6Cg7AymzilOnA2db0UY8k1Joc-b059UryfbC5m9Lm3wwDBxikbqevWpWRViI_CPsWck3UPXgg2h9gOXFNjMzU2c4itlrz8d4a_BaecquDVibmOYXXvq8sF9N-dH6yhTFKuOs7-AH0voss</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68284663</pqid></control><display><type>article</type><title>Insulin sensitizers in treatment of nonalcoholic fatty liver disease： Systematic review</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Chavez-Tapia, Norberto-C ; Barrientos-Gutierrez, Tonatiuh ; Tellez-Avila, Felix-I ; Sanchez-Avila, Francisco ; Montano-Reyes, Maria-Antonieta ; Uribe, Misael</creator><creatorcontrib>Chavez-Tapia, Norberto-C ; Barrientos-Gutierrez, Tonatiuh ; Tellez-Avila, Felix-I ; Sanchez-Avila, Francisco ; Montano-Reyes, Maria-Antonieta ; Uribe, Misael</creatorcontrib><description>AIM： To summarize the evidence available for the clinical effectiveness of insulin sensitizers in the treatment of nonalcoholic fatty liver disease （NAFLD） systematically.
METHODS： Relevant articles were located using computer-assisted searches of Medline （1966-March 2006）, EMBASE （1988-March 2006）, CINAHL （1982-March 2003）, Educational Resource Information Center （1966-March 2006）, Library, Information Science ＆ Technology Abstracts （1967-March 2006）, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects （1994-2006）, dissertations in ProQuest and FirstSearch databases. Manual searches were made in the abstracts from meetings of the American Gastroenterological Association （1999-2006）, and the American Association for the Study of Liver Diseases （2003-2005）. Studies were retrieved using the following selection criteria： （1） clinical trials using insulin sensitizers in subjects with NAFLD, （2） adult patients, （3） published as full manuscripts or abstracts, and （4） English, Spanish, German, and French languages only. Data were abstracted independently by two reviewers following standardized procedures. A face-toface comparison of data was conducted to ensure the completeness and reliability of the abstraction process.
RESULTS： Nine studies were included, six using metformin and three using thiazolidinediones. Only two studies were placebo-controlled trials. The median sample size for all studies was 18 subjects. In the placebo-controlled trials, metformin improved insulin resistance markers and liver function tests, but not histological scores. In the single-arm trials, metformin and thiazolidinediones improved insulin resistance markers and liver function tests, and beneficial histological changes were reported. There is limited high-quality information available from which to draw categorical conclusions about the clinical use of insulin sensitizers in NAFLD.
CONCLUSION： Current information indicates that the use of insulin sensitizers in NAFLD improves insulin resistance and liver function. Histological changes must be corroborated in randomized controlled trials.</description><identifier>ISSN: 1007-9327</identifier><identifier>EISSN: 2219-2840</identifier><identifier>DOI: 10.3748/wjg.v12.i48.7826</identifier><identifier>PMID: 17203528</identifier><language>eng</language><publisher>United States: Department of Gastroenterology,Instituto Nacional de Ciencias Médicas y Nutrición Zalvador Zubirán, Mexico City, Mexico%The University of Texas School of Public Health, Houston, United States%Instituto de Educación Media Superior, Mexico City, Mexico</publisher><subject>Controlled Clinical Trials as Topic ; Diet, Carbohydrate-Restricted ; Fatty Liver - drug therapy ; Fatty Liver - pathology ; Fatty Liver - physiopathology ; Humans ; Hypoglycemic Agents - therapeutic use ; Insulin - physiology ; Insulin Resistance - physiology ; Liver - physiopathology ; Metformin - therapeutic use ; Rapid Communication ; Thiazolidinediones - therapeutic use ; 敏化剂 ; 非酒精性脂肪肝</subject><ispartof>World journal of gastroenterology : WJG, 2006-12, Vol.12 (48), p.7826-7831</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><rights>2006 Baishideng Publishing Group Co., Limited. All rights reserved. 2006</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-f367e18aa5a8f1af099b3c5f05889f77097e5631a465f54539c059a3537b7d673</citedby><cites>FETCH-LOGICAL-c450t-f367e18aa5a8f1af099b3c5f05889f77097e5631a465f54539c059a3537b7d673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/84123X/84123X.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087550/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087550/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17203528$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chavez-Tapia, Norberto-C</creatorcontrib><creatorcontrib>Barrientos-Gutierrez, Tonatiuh</creatorcontrib><creatorcontrib>Tellez-Avila, Felix-I</creatorcontrib><creatorcontrib>Sanchez-Avila, Francisco</creatorcontrib><creatorcontrib>Montano-Reyes, Maria-Antonieta</creatorcontrib><creatorcontrib>Uribe, Misael</creatorcontrib><title>Insulin sensitizers in treatment of nonalcoholic fatty liver disease： Systematic review</title><title>World journal of gastroenterology : WJG</title><addtitle>World Journal of Gastroenterology</addtitle><description>AIM： To summarize the evidence available for the clinical effectiveness of insulin sensitizers in the treatment of nonalcoholic fatty liver disease （NAFLD） systematically.
METHODS： Relevant articles were located using computer-assisted searches of Medline （1966-March 2006）, EMBASE （1988-March 2006）, CINAHL （1982-March 2003）, Educational Resource Information Center （1966-March 2006）, Library, Information Science ＆ Technology Abstracts （1967-March 2006）, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects （1994-2006）, dissertations in ProQuest and FirstSearch databases. Manual searches were made in the abstracts from meetings of the American Gastroenterological Association （1999-2006）, and the American Association for the Study of Liver Diseases （2003-2005）. Studies were retrieved using the following selection criteria： （1） clinical trials using insulin sensitizers in subjects with NAFLD, （2） adult patients, （3） published as full manuscripts or abstracts, and （4） English, Spanish, German, and French languages only. Data were abstracted independently by two reviewers following standardized procedures. A face-toface comparison of data was conducted to ensure the completeness and reliability of the abstraction process.
RESULTS： Nine studies were included, six using metformin and three using thiazolidinediones. Only two studies were placebo-controlled trials. The median sample size for all studies was 18 subjects. In the placebo-controlled trials, metformin improved insulin resistance markers and liver function tests, but not histological scores. In the single-arm trials, metformin and thiazolidinediones improved insulin resistance markers and liver function tests, and beneficial histological changes were reported. There is limited high-quality information available from which to draw categorical conclusions about the clinical use of insulin sensitizers in NAFLD.
CONCLUSION： Current information indicates that the use of insulin sensitizers in NAFLD improves insulin resistance and liver function. Histological changes must be corroborated in randomized controlled trials.</description><subject>Controlled Clinical Trials as Topic</subject><subject>Diet, Carbohydrate-Restricted</subject><subject>Fatty Liver - drug therapy</subject><subject>Fatty Liver - pathology</subject><subject>Fatty Liver - physiopathology</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - physiology</subject><subject>Insulin Resistance - physiology</subject><subject>Liver - physiopathology</subject><subject>Metformin - therapeutic use</subject><subject>Rapid Communication</subject><subject>Thiazolidinediones - therapeutic use</subject><subject>敏化剂</subject><subject>非酒精性脂肪肝</subject><issn>1007-9327</issn><issn>2219-2840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkc1uEzEUhS1ERUNhzwqNEGI3qf_t2SChip9KlVgUFqysm4mdOMzYre1JFB6FZ-GdeAUcJSqwsi2f-91z70HoBcFzpri-3G1W8y2hc8_1XGkqH6EZpaRrqeb4MZoRjFXbMarO0dOcNxhTxgR9gs6Jorje9Ax9uw55Gnxosg3ZF__DptzUZ0kWymhDaaJrQgww9HEdB983DkrZN4Pf2tQsfbaQ7e9fP5vbfS52hFIVyW693T1DZw6GbJ-fzgv09cP7L1ef2pvPH6-v3t20PRe4tI5JZYkGEKAdAYe7bsF64bDQunNK4U5ZIRkBLoUTXLCux6IDJphaqKVU7AK9PXLvpsVol331nGAwd8mPkPYmgjf__wS_Nqu4NRxrJQSugNdHwA6Cg7AymzilOnA2db0UY8k1Joc-b059UryfbC5m9Lm3wwDBxikbqevWpWRViI_CPsWck3UPXgg2h9gOXFNjMzU2c4itlrz8d4a_BaecquDVibmOYXXvq8sF9N-dH6yhTFKuOs7-AH0voss</recordid><startdate>20061228</startdate><enddate>20061228</enddate><creator>Chavez-Tapia, Norberto-C</creator><creator>Barrientos-Gutierrez, Tonatiuh</creator><creator>Tellez-Avila, Felix-I</creator><creator>Sanchez-Avila, Francisco</creator><creator>Montano-Reyes, Maria-Antonieta</creator><creator>Uribe, Misael</creator><general>Department of Gastroenterology,Instituto Nacional de Ciencias Médicas y Nutrición Zalvador Zubirán, Mexico City, Mexico%The University of Texas School of Public Health, Houston, United States%Instituto de Educación Media Superior, Mexico City, Mexico</general><general>Baishideng Publishing Group Co., Limited</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope><scope>5PM</scope></search><sort><creationdate>20061228</creationdate><title>Insulin sensitizers in treatment of nonalcoholic fatty liver disease： Systematic review</title><author>Chavez-Tapia, Norberto-C ; Barrientos-Gutierrez, Tonatiuh ; Tellez-Avila, Felix-I ; Sanchez-Avila, Francisco ; Montano-Reyes, Maria-Antonieta ; Uribe, Misael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-f367e18aa5a8f1af099b3c5f05889f77097e5631a465f54539c059a3537b7d673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Controlled Clinical Trials as Topic</topic><topic>Diet, Carbohydrate-Restricted</topic><topic>Fatty Liver - drug therapy</topic><topic>Fatty Liver - pathology</topic><topic>Fatty Liver - physiopathology</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - physiology</topic><topic>Insulin Resistance - physiology</topic><topic>Liver - physiopathology</topic><topic>Metformin - therapeutic use</topic><topic>Rapid Communication</topic><topic>Thiazolidinediones - therapeutic use</topic><topic>敏化剂</topic><topic>非酒精性脂肪肝</topic><toplevel>online_resources</toplevel><creatorcontrib>Chavez-Tapia, Norberto-C</creatorcontrib><creatorcontrib>Barrientos-Gutierrez, Tonatiuh</creatorcontrib><creatorcontrib>Tellez-Avila, Felix-I</creatorcontrib><creatorcontrib>Sanchez-Avila, Francisco</creatorcontrib><creatorcontrib>Montano-Reyes, Maria-Antonieta</creatorcontrib><creatorcontrib>Uribe, Misael</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastroenterology : WJG</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chavez-Tapia, Norberto-C</au><au>Barrientos-Gutierrez, Tonatiuh</au><au>Tellez-Avila, Felix-I</au><au>Sanchez-Avila, Francisco</au><au>Montano-Reyes, Maria-Antonieta</au><au>Uribe, Misael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insulin sensitizers in treatment of nonalcoholic fatty liver disease： Systematic review</atitle><jtitle>World journal of gastroenterology : WJG</jtitle><addtitle>World Journal of Gastroenterology</addtitle><date>2006-12-28</date><risdate>2006</risdate><volume>12</volume><issue>48</issue><spage>7826</spage><epage>7831</epage><pages>7826-7831</pages><issn>1007-9327</issn><eissn>2219-2840</eissn><abstract>AIM： To summarize the evidence available for the clinical effectiveness of insulin sensitizers in the treatment of nonalcoholic fatty liver disease （NAFLD） systematically.
METHODS： Relevant articles were located using computer-assisted searches of Medline （1966-March 2006）, EMBASE （1988-March 2006）, CINAHL （1982-March 2003）, Educational Resource Information Center （1966-March 2006）, Library, Information Science ＆ Technology Abstracts （1967-March 2006）, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects （1994-2006）, dissertations in ProQuest and FirstSearch databases. Manual searches were made in the abstracts from meetings of the American Gastroenterological Association （1999-2006）, and the American Association for the Study of Liver Diseases （2003-2005）. Studies were retrieved using the following selection criteria： （1） clinical trials using insulin sensitizers in subjects with NAFLD, （2） adult patients, （3） published as full manuscripts or abstracts, and （4） English, Spanish, German, and French languages only. Data were abstracted independently by two reviewers following standardized procedures. A face-toface comparison of data was conducted to ensure the completeness and reliability of the abstraction process.
RESULTS： Nine studies were included, six using metformin and three using thiazolidinediones. Only two studies were placebo-controlled trials. The median sample size for all studies was 18 subjects. In the placebo-controlled trials, metformin improved insulin resistance markers and liver function tests, but not histological scores. In the single-arm trials, metformin and thiazolidinediones improved insulin resistance markers and liver function tests, and beneficial histological changes were reported. There is limited high-quality information available from which to draw categorical conclusions about the clinical use of insulin sensitizers in NAFLD.
CONCLUSION： Current information indicates that the use of insulin sensitizers in NAFLD improves insulin resistance and liver function. Histological changes must be corroborated in randomized controlled trials.</abstract><cop>United States</cop><pub>Department of Gastroenterology,Instituto Nacional de Ciencias Médicas y Nutrición Zalvador Zubirán, Mexico City, Mexico%The University of Texas School of Public Health, Houston, United States%Instituto de Educación Media Superior, Mexico City, Mexico</pub><pmid>17203528</pmid><doi>10.3748/wjg.v12.i48.7826</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1007-9327 |
| ispartof | World journal of gastroenterology : WJG, 2006-12, Vol.12 (48), p.7826-7831 |
| issn | 1007-9327 2219-2840 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4087550 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Controlled Clinical Trials as Topic Diet, Carbohydrate-Restricted Fatty Liver - drug therapy Fatty Liver - pathology Fatty Liver - physiopathology Humans Hypoglycemic Agents - therapeutic use Insulin - physiology Insulin Resistance - physiology Liver - physiopathology Metformin - therapeutic use Rapid Communication Thiazolidinediones - therapeutic use 敏化剂 非酒精性脂肪肝 |
| title | Insulin sensitizers in treatment of nonalcoholic fatty liver disease： Systematic review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T23%3A01%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insulin%20sensitizers%20in%20treatment%20of%20nonalcoholic%20fatty%20liver%20disease%EF%BC%9A%20Systematic%20review&rft.jtitle=World%20journal%20of%20gastroenterology%20:%20WJG&rft.au=Chavez-Tapia,%20Norberto-C&rft.date=2006-12-28&rft.volume=12&rft.issue=48&rft.spage=7826&rft.epage=7831&rft.pages=7826-7831&rft.issn=1007-9327&rft.eissn=2219-2840&rft_id=info:doi/10.3748/wjg.v12.i48.7826&rft_dat=%3Cwanfang_jour_pubme%3Ewjg200648017%3C/wanfang_jour_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68284663&rft_id=info:pmid/17203528&rft_cqvip_id=23624794&rft_wanfj_id=wjg200648017&rfr_iscdi=true |